A high-content phenotypic screen reveals the disruptive potency of quinacrine and 3',4'-Dichlorobenzamil on the digestive vacuole of plasmodium falciparum

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 1, 2014, Pages 550-558

  Lee, Yan Q ^a,b   Goh, Amanda S P ^a   Ch'Ng, Jun H ^a   Nosten, François H ^c   Preiser, Peter R ^d   Pervaiz, Shazib ^e   Yadav, Sanjiv K ^e   Tan, Kevin S W ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c SHOKLO MALARIA RESEARCH UNIT   (Thailand)

^d NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

1,5 BIS(4 ALLYLDIMETHYLAMMONIUMPHENYL)PENTAN 3 ONE DIBROMIDE; 2 DIPROPYLAMINO 5 FLUORO 8 HYDROXYTETRALIN; 3',4' DICHLOROBENZAMIL; AFIMOXIFENE; ARTEMISININ; BENZAMIL; CALCIUM; CHLOROQUINE; CHLORPROMAZINE; CINCHONINE; DESIPRAMINE; EMETINE; FLUORESCENT DYE; HALOFANTRINE; MEFLOQUINE; MEPACRINE; PROMETHAZINE; QUINIDINE; QUININE; SULFADOXINE; VINBLASTINE; VINCRISTINE; ZOLANTIDINE;

ANTIMALARIAL ACTIVITY; ANTIMALARIAL DRUG SUSCEPTIBILITY; APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CELL PERMEABILIZATION; CELL VACUOLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFICACY; DRUG POTENCY; FLOW CYTOMETRY; HIGH THROUGHPUT SCREENING; IC 50; MALARIA FALCIPARUM; NONHUMAN; PARASITE ISOLATION; PHENOTYPE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL;

AMILORIDE; ANTIMALARIALS; PLASMODIUM FALCIPARUM; QUINACRINE; VACUOLES;

EID: 84891501995     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01441-13     Document Type: Article

References (39)

1. World Health Organization. 2012. World malaria report 2012. World Health Organization, Geneva, Switzerland. http://www.who.int/malaria/publications/ world-malaria-report-2012/report/en/index.html.
2. Mita T, Tanabe K. 2012. Evolution of Plasmodium falciparum drug resistance: implications for the development and containment of artemisinin resistance. Jpn. J. Infect. Dis. 65:465-475. http://dx.doi.org/10.7883/yoken.65. 465.
3. Takala-Harrison S, Clark TG, Jacob CG, Cummings MP, Miotto O, Dondorp AM, Fukuda MM, Nosten F, Noedl H, Imwong M, Bethell D, Se Y, Lon C, Tyner SD, Saunders DL, Socheat D, Ariey F, Phyo AP, Starzengruber P, Fuehrer H-P, Swoboda P, Stepniewska K, Flegg J, Arze C, Cerqueira GC, Silva JC, Ricklefs SM, Porcella SF, Stephens RM, Adams M, Kenefic LJ, Campino S, Auburn S, MacInnis B, Kwiatkowski DP, Su X, White NJ, Ringwald P, Plowe CV. 2013. Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia. Proc. Natl. Acad. Sci. U. S. A. 110:240- 245. http://dx.doi.org/10.1073/pnas.1211205110.
4. Ch'ng J-H, Kotturi SR, Chong AG-L, Lear MJ, Tan KS-W. 2010. A programmed cell death pathway in the malaria parasite Plasmodium falciparum has general features of mammalian apoptosis but is mediated by clan CA cysteine proteases. Cell Death Dis. 1:e26. http://dx.doi.org/10.1038/cddis.2010.2.
5. Ch'ng J-H, Liew K, Goh AS-P, Sidhartha E, Tan KS-W. 2011. Druginduced permeabilization of parasite's digestive vacuole is a key trigger of programmed cell death in Plasmodium falciparum. Cell Death Dis. 2:e216. http://dx.doi.org/10.1038/cddis.2011.97.
6. Ch'ng J-H, Mok S, Bozdech Z, Lear MJ, Boudhar A, Russell B, Nosten F, Tan KS-W. 2013. A whole cell pathway screen reveals seven novel chemosensitizers to combat chloroquine resistant malaria. Sci. Rep. 3:1734. http://dx.doi.org/10. 1038/srep01734.
7. Laufer MK, Thesing PC, Dzinjalamala FK, Nyirenda OM, Masonga R, Laurens MB, Stokes-Riner A, Taylor TE, Plowe CV. 2012. A longitudinal trial comparing chloroquine as monotherapy or in combination with artesunate, azithromycin or atovaquone-proguanil to treat malaria. PLoS One 7:e42284. http://dx.doi.org/10. 1371/journal.pone.0042284.
8. Ginsburg H, Ward S, Bray P. 1999. An integrated model of chloroquine action. Parasitol. Today 15:357-360. http://dx.doi.org/10.1016/S0169-4758(99) 01502-1.
9. Rohrbach P, Friedrich O, Hentschel J, Plattner H, Fink RHA, Lanzer M. 2005. Quantitative calcium measurements in subcellular compartments of Plasmodium falciparum-infected erythrocytes. J. Biol. Chem. 280: 27960-27969. http://dx.doi.org/10.1074/jbc.M500777200.
10. Lucumi E, Darling C, Jo H, Napper AD, Chandramohanadas R, Fisher N, Shone AE, Jing H, Ward SA, Biagini GA, DeGrado WF, Diamond SL, Greenbaum DC. 2010. Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based assay. Antimicrob. Agents Chemother. 54:3597-3604. http://dx.doi.org/10.1128/AAC.00431- 10.
11. Bohórquez EB, Chua M, Meshnick SR. 2012. Quinine localizes to a non-acidic compartment within the food vacuole of the malaria parasite Plasmodium falciparum. Malar. J. 11:350. http://dx.doi.org/10.1186/1475-2875-11- 350.
12. Peti-Peterdi J, Fintha A, Fuson AL, Tousson A, Chow RH. 2004. Real-time imaging of renin release in vitro. Am. J. Physiol. Renal Physiol. 287:F329-F335. http://dx.doi.org/10.1152/ajprenal.00420.2003.
13. Vermes I, Haanen C, Reutelingsperger C. 2000. Flow cytometry of apoptotic cell death. J. Immunol. Methods 243:167-190. http://dx.doi.org/10.1016/S0022- 1759(00)00233-7.
14. Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, Lassota P, Traganos F. 1992. Features of apoptotic cells measured by flow cytometry. Cytometry 13:795-808. http://dx.doi.org/10.1002/cyto.990130802.
15. Zhang X. 2008. Genome-wide screens for effective siRNAs through assessing the size of siRNA effects. BMC Res. Notes 1:33. http://dx.doi.org/10.1186/1756- 0500-1-33.
16. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. 2007. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6:29-40. http://dx.doi.org/10.1038/nrd2201.
17. Love MS, Millholland MG, Mishra S, Kulkarni S, Freeman KB, Pan W, Kavash RW, Costanzo MJ, Jo H, Daly TM, Williams DR, Kowalska MA, Bergman LW, Poncz M, DeGrado WF, Sinnis P, Scott RW, Greenbaum DC. 2012. Platelet factor 4 activity against P. falciparum and its translation to nonpeptidic mimics as antimalarials. Cell Host Microbe 12:815-823. http://dx.doi.org/10.1016/j.chom. 2012.10.017.
18. Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, Ursos LMB, bir Singh Sidhu A, Naudé B, Deitsch KW, Su X, Wootton JC, Roepe PD, Wellems TE. 2000. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol. Cell 6:861-871. http://dx.doi.org/10.1016/S1097-2765(05)00077-8.
19. Chen N, Kyle DE, Pasay C, Fowler EV, Baker J, Peters JM, Cheng Q. 2003. pfcrt allelic types with two novel amino acid mutations in chloroquine- resistant Plasmodium falciparum isolates from the Philippines. Antimicrob. Agents Chemother. 47:3500-3505. http://dx.doi.org/10.1128/AAC.47.11.3500-3505. 2003.
20. Sidhu ABS, Verdier-Pinard D, Fidock DA. 2002. Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science 298:210-213. http://dx.doi.org/10.1126/science.1074045.
21. Sanchez CP, McLean JE, Stein W, Lanzer M. 2004. Evidence for a substrate specific and inhibitable drug efflux system in chloroquine resistant Plasmodium falciparum strains. Biochemistry 43:16365-16373. http://dx.doi.org/10.1021/ bi048241x.
22. Sanchez CP, Stein W, Lanzer M. 2003. Trans stimulation provides evidence for a drug efflux carrier as the mechanism of chloroquine resistance in Plasmodium falciparum. Biochemistry 42:9383-9394. http://dx.doi.org/10.1021/ bi034269h.
23. Paguio MF, Cabrera M, Roepe PD. 2009. Chloroquine transport in Plasmodium falciparum. 2. Analysis of PfCRT-mediated drug transport using proteoliposomes and a fluorescent chloroquine probe. Biochemistry 48:9482-9491. http://dx.doi.org/10.1021/bi901035j.
24. Price RN, Cassar C, Brockman A, Duraisingh M, Vugt M van, White NJ, Nosten F, Krishna S. 1999. The pfmdr1 gene is associated with a multidrug-resistant phenotype in Plasmodium falciparum from the western border of Thailand. Antimicrob. Agents Chemother. 43:2943-2949.
25. Lim P, Alker AP, Khim N, Shah NK, Incardona S, Doung S, Yi P, Bouth DM, Bouchier C, Puijalon OM, Meshnick SR, Wongsrichanalai C, Fandeur T, Bras JL, Ringwald P, Ariey F. 2009. Pfmdr1 copy number and arteminisin derivatives combination therapy failure in falciparum malaria in Cambodia. Malar. J. 8:11. http://dx.doi.org/10.1186/1475-2875-8-11.
26. Veiga MI, Ferreira PE, Jörnhagen Malmberg LM, Kone A, Schmidt BA, Petzold M, Björkman A, Nosten F, Gil JP. 2011. Novel polymorphisms in Plasmodium falciparum ABC transporter genes are associated with major ACT antimalarial drug resistance. PLoS One 6:e20212. http://dx.doi.org/10.1371/ journal.pone.0020212.
27. Pirahmadi S, Zakeri S, Afsharpad M, Djadid ND. 2013. Mutation analysis in pfmdr1 and pfmrp1 as potential candidate genes for artemisinin resistance in Plasmodium falciparum clinical isolates 4 years after implementation of artemisinin combination therapy in Iran. Infect. Genet. Evol. 14:327-334. http://dx.doi.org/10.1016/j.meegid.2012.12.014.
28. 2+ exchanger inhibitors inhibit neurite outgrowth in PC12 cells. J. Pharmacol. Sci. 116:128-131. http://dx.doi.org/10.1254/jphs. 11011SC.
29. 2+ oscillation causes cell death in intraerythrocitic Plasmodium falciparum. PLoS One 7:e39499. http://dx.doi.org/10.1371/journal.pone.0039499.
30. Adovelande J, Bastide B, Deleze J, Schrevel J. 1993. Cytosolic free calcium in Plasmodium falciparum-infected erythrocytes and the effect of verapamil: a cytofluorometric study. Exp. Parasitol. 76:247-258. http://dx.doi.org/10.1006/expr.1993.1030.
31. 2+. Antimicrob. Agents Chemother. 49:4807-4808. http://dx.doi.org/10.1128/AAC.49.11.4807-4808.2005.
32. Martin SK, Oduola AMJ, Milhous WK. 1987. Reversal of chloroquine resistance in Plasmodium falciparum by verapamil. Science 235:899-901. http://dx.doi.org/10.1126/science.3544220.
33. Tanenbaum LTD. 1980. Antimalarial agents: chloroquine, hydroxychloroquine, and quinacrine. Arch. Dermatol. 116:587-591. http://dx.doi.org/10.1001/archderm.1980.01640290097026.
34. Loria P, Miller S, Foley M, Tilley L. 1999. Inhibition of the peroxidative degradation of haem as the basis of action of chloroquine and other quinoline antimalarials. Biochem. J. 339:363-370. http://dx.doi.org/10.1042/ 0264-6021:3390363.
35. Bhattacharjee AK, Kyle DE, Vennerstrom JL, Milhous WK. 2002. A 3D QSAR pharmacophore model and quantum chemical structure-activity analysis of chloroquine (CQ)-resistance reversal. J. Chem. Inf. Comput. Sci. 42:1212-1220. http://dx.doi.org/10.1021/ci0200265.
36. Shannon JA, Earle DP, Brodie BB, Taggart JV, Berliner RW. 1944. The pharmacological basis for the rational use of atabrine in the treatment of malaria. J. Pharmacol. Exp. Ther. 81:307-330. http://citeseerx.ist.psu.edu/ viewdoc/download?doi-10.1.1.32.2459&rep-rep1&type-pdf
37. Youngster DI, Arcavi L, Schechmaster R, Akayzen Y, Popliski H, Shimonov J, Beig S, Berkovitch M. 2010. Medications and glucose-6- phosphate dehydrogenase deficiency. Drug Saf. 33:713-726. http://dx.doi.org/10.2165/ 11536520-000000000-00000.
38. Maitland K, Newton CRJC. 2005. Acidosis of severe falciparum malaria: heading for a shock? Trends Parasitol. 21:11-16. http://dx.doi.org/10.1016/j.pt. 2004.10.010.
39. Evans BC, Nelson CE, Yu SS, Beavers KR, Kim AJ, Li H, Nelson HM, Giorgio TD, Duvall CL. 2013. Ex vivo red blood cell hemolysis assay for the evaluation of pH-responsive endosomolytic agents for cytosolic delivery of biomacromolecular drugs. J. Vis. Exp. 73:e50166. http://dx.doi.org/10.3791/ 50166.